61 patients with advanced bladder cancer were treated with methotrexate. 3 different regimes were used, 2 given on an out-patient and 1 on an in-patient basis. A response rate of 56% was found in patients who received 100 mg of methotrexate intravenously every 2 weeks as an out-patient. Provided that renal function is checked before therapy and is normal, then methotrexate can be used safely; it being well tolerated and having few serious side-effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1464-410x.1977.tb04551.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human head and neck cancer cell lines response to cold atmospheric plasma activated media is affected by the chemistry of culture media.
Heliyon
January 2025
UdA-TechLab, Research Center, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
Survival rate of head and neck squamous cell carcinomas (HNSCC) patients are still to date very poor, and the application of innovative clinical approaches are urgently needed. Cold atmospheric plasmas (CAPs) are partially ionized gases that have shown anti-tumor effectiveness over a wide range of cancer types with potential application into clinics. However, the comprehension of the mechanisms underlying indirect CAP effects plays a key role for the prediction of treatment outcomes.
View Article and Find Full Text PDFOffice-Based Endoscopic Urological Procedures Under Local Anesthesia: Prospective Evaluation of Feasibility, Pain, and Patient Preference.
J Endourol
January 2025
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Several diagnostic and therapeutic endoscopic urological procedures, such as stent placement, ureteroscopy, and bladder stone lithotripsy, can be performed in a hospital, an ambulatory surgery center, in the office with IV sedation, or in the office using only topical anesthesia. The potential benefits of performing procedures in the office setting using topical anesthesia include efficiency and cost reduction. The potential harms are failure to achieve the desired outcome and patient pain.
View Article and Find Full Text PDFRecent Advances in Nanotherapeutics and Theranostics for Squamous Cell Carcinoma: A Comprehensive Review.
Curr Drug Deliv
January 2025
Laboratory of Molecular Medicine, Birla Institute of Technology and Sciences Pilani Hyderabad Campus, 500071, India.
Recent advancements in nanotherapeutics have revolutionized cancer treatment through the integration of diagnostic and therapeutic modalities, known as theranostics. This critical review examines the current landscape of nanotherapeutics for various cancers, such as bladder and head and neck squamous cell carcinoma, highlighting current advancements in nanotherapeutics and challenges. Key approaches discussed include biomimetic smart nanocarriers, polymeric smart nanocarriers, inorganic-based smart nanocarriers, and nanorobots.
View Article and Find Full Text PDFUrogenital Cancer Epidemiology in Poland (1980-2020): A Narrative Review.
Cancers (Basel)
January 2025
Department of Urology and Oncological Urology, MSWiA Hospital, Warmian-Masurian Cancer Center, 10-228 Olsztyn, Poland.
Despite advances in prophylaxis, early diagnosis, and treatment, urogenital cancers represent a significant challenge to public health in Poland due to their relatively high prevalence and mortality rates. This narrative review aims to explore contemporary evidence on the epidemiology of urogenital cancers in Poland, such as prostate cancer, bladder cancer, kidney cancer, testicular cancer, and penile cancer, focusing on current and historical status and trends in the broader context of healthcare delivery. The literature consistently indicates that urogenital cancer continues to be a significant contributor to cancer incidence and mortality rates in Poland.
View Article and Find Full Text PDFNuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions.
Cancers (Basel)
January 2025
Urology Department, South Metropolitan Health Service, Murdoch, WA, 6150, Australia.
: The role of molecular imaging in urothelial cancer is less defined than other cancers, and its utility remains controversial due to limitations such as high urinary tracer excretion, complicating primary tumour assessment in the bladder and upper urinary tract. This review explores the current landscape of PET imaging in the clinical management of urothelial cancer, with a special emphasis on potential future advancements including emerging novel non-F FDG PET agents, PET radiopharmaceuticals, and PET-MRI applications. : We conducted a comprehensive literature search in the PubMed database, using keywords such as "PET", "PET-CT", "PET-MRI", "FDG PET", "Urothelial Cancer", and "Theranostics".
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!